Phreesia Investors Face a Bad Check-In: Securities Suit Alleges Stock Was Artificially Inflated

According to the complaint, Phreesia sold investors on a growth story. Its healthcare platform was expanding. AI tools were gaining traction. Pharma marketing demand appeared strong. Network Solutions visibility looked similar to the year before.

But investors now allege that picture was misleading.

Throughout 2025, according to the complaint, Phreesia touted its Network Solutions business and pointed to pharmaceutical spending commitments as a growth driver. The company even projected up to about $559 million in fiscal 2027 revenue.

Then came March 30, 2026.

Phreesia suddenly slashed its fiscal 2027 outlook by tens of millions of dollars. Executives said certain pharmaceutical manufacturers were committing lower spend levels and visibility into future spending had worsened.

Investors and analysts reacted immediately.

The stock dropped about 27% in a single day after the disclosure.

Now, shareholders are learning more about their potential claims.